seen from Canada
seen from United States
seen from Türkiye
seen from Argentina
seen from Syria
seen from Canada
seen from United States
seen from Australia
seen from China
seen from United States
seen from Türkiye
seen from China
seen from China
seen from Canada
seen from Netherlands
seen from United States
seen from China
seen from China
seen from China
seen from Japan
Novartis has announced results from the Monaleesa-3 trial at the European Society for Medical Oncology (ESMO) Congress 2019.
Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.
At ESMO 2019, Samsung Bioepis reveals positive results from Phase 3 study comparing its SB8 with Avastin in patients with metastatic or recurrent NSCLC.
A Phase 3 study comparing Samsung Bioepis’ SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).
